3D Medicines Inc. (1244)

Overview

3D Medicines Inc. is a biopharmaceutical entity engaged in the discovery, development, and commercialization of innovative oncology treatments. Founded in 2014 and based in Qingdao, China, the company dedicates its efforts to addressing the unmet medical needs of cancer patients within Mainland China. It specializes in the development of drug candidates and oncology products, employing cutting-edge scientific research to offer novel therapeutic options for various types of cancers. Through its robust research and development program, 3D Medicines Inc. aims to advance the field of cancer treatment, making significant contributions to the global fight against this disease.

Products and Services

• Envafolimab:

  A pioneering PD-L1 antibody developed as a subcutaneous injection specifically designed for patients with previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors. This product represents 3D Medicines Inc.'s commitment to offering innovative treatments for complex oncological conditions.

• 3D189:

  This multi-indication tumor drug is currently in phase III clinical trial, highlighting the company's continuous efforts in expanding its pipeline with treatments that hold promise across a broad spectrum of cancers.

• 3D229 (GAS6/AXL):

  Targeting non-small cell lung cancer, ovarian cancer, and kidney cancer, 3D229 is in phase III clinical trial. This product underscores the company’s dedication to tackling some of the most challenging cancers with novel mechanisms of action.

• 3D1001:

  Developed for the treatment of postoperative dental pain and tumor pain, 3D1001 is in a phase II trial. This indicates the company's efforts to address not only the oncologic aspect of patient care but also the quality of life issues such as pain management.

• 3D1002:

  A phase II trial candidate for oncology pain, showcasing 3D Medicines Inc.'s commitment to improving patient outcomes by focusing on the alleviation of pain associated with cancer.

• 3D185:

  In phase I clinical trial, this compound is being tested for the treatment of locally advanced or metastatic solid tumors, further expanding the company’s diverse portfolio of cancer therapies.

• Additional Products:

  The company’s pipeline also includes 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors, illustrating 3D Medicines Inc.'s broad approach towards cancer treatment through diverse and innovative therapeutic candidates.